The DOI matches its Crossref record.
Effect of a Reversible Monoamine Oxidase-A Inhibitor (Moclobemide) on Sleep of Depressed Patients
Abstract
The effect of moclobemide, a short-acting, reversible, preferential monoamine oxidase-A inhibitor in a 4-week therapeutic trial, on the sleep of ten depressed patients, was assessed by polysomnographic recordings. Compared with their time on placebo, patients receiving moclobemide showed improved sleep continuity, particularly during the intermediate and late stages of drug administration. The total increase in sleep time was comprised of larger amounts of stage 2 non-rapid eye movement (NREM) sleep and rapid eye movement (REM) sleep. Withdrawal of moclobemide was followed by a further increase of REM sleep, although values did not surpass those sometimes observed in adults with normal sleep. In these patients, the symptoms of depression were rated as being significantly improved during the study period.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Suppression of REM by newer reversible monoamine oxidase-A inhibitors such as moclobemide appears to be much less pronounced or possibly not present at all.
“Suppression of REM by the newer reversible monoamine oxidase-A inhibitors such as moclobemide appears to be much less pronounced or possibly not present at all [Monti, 1989].”
From Depression, sleep physiology, and antidepressant drugs (2001) · cites this paper as Monti, 1989
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 29
- 10.1001/archpsyc.1971.01750080049007 · DOI · Paper page
- 10.1016/0013-4694(67)90174-5 · DOI
- Amrein, 1988, Antidepressant drug therapy: associated risks, Journal of Neural Transmission, 26, 73
- Passouant, 1973, La suppression du sommeil paradoxal par la clomipramine, Thérapie, 28, 379
- 10.1001/archpsyc.1973.01750330045008 · DOI
- 10.1111/j.1600-0447.1985.tb08071.x · DOI
- 10.1016/0278-5846(87)90032-7 · DOI
- 10.1001/archpsyc.1980.01780160017001 · DOI
- Kupfer, 1983, Treatment of Depression: Old Controversies and New Approaches
- 10.1016/0013-4694(70)90078-7 · DOI
- 10.1055/s-2007-1017119 · DOI
- 10.1007/BF00427316 · DOI · Paper page
- 10.1192/bjp.120.559.663 · DOI
- 10.1055/s-2007-1017193 · DOI · Paper page
- 10.1111/j.1365-2125.1983.tb04977.x · DOI · Paper page
- Rechtschaffen, 1968, National Institutes of Health Publication, 204
- 10.1097/00004714-198202000-00003 · DOI
- Gillin, 1984, Neurobiology of Mood Disorders
- 10.1056/NEJM198808183190706 · DOI
- 10.1192/bjp.111.473.357 · DOI
- 10.1007/BF00426633 · DOI
- Zung, 1980, A comparison of the effects of viloxazine and placebo on the sleep of depressed patients, Current Therapeutic Research, 27, 152
- 10.1007/BF00172629 · DOI · Paper page
- 10.1093/sleep/10.3.199 · DOI
- 10.1185/03007998009109467 · DOI
- Da Prada, 1988, On tyramine, food, beverages and the reversible MAO inhibitor moclobemide, Journal of Neural Transmission, 26, 31
- 10.1007/BF00426203 · DOI
- Kupfer, 1981, Sleep and treatment prediction in endogenous depression, American Journal of Psychiatry, 138, 429, 10.1176/ajp.138.4.429 · DOI
- 10.1055/s-2007-1017219 · DOI
Cited by
Sorted by citations
Depression, sleep physiology, and antidepressant drugs
Winokur, A., Gary, K. A., Rodner, S., Rae-Red, C., Fernando, A. T., & Szuba, M. P. (2001) · Depression and Anxiety · doi:10.1002/da.1043 · Cited by 179
Mendlewicz, J. (2009) · The World Journal of Biological Psychiatry · doi:10.3109/15622970802503086 · Cited by 143
Effects of Antidepressant Treatment on Sleep EEG in Depression
Armitage, R. (1996) · Journal of Psychopharmacology · doi:10.1177/026988119601001s01 · Cited by 18
Metadata
- Authors
- Monti, J. M.
- Affiliations
- Hospital de Clínicas (UY)
- Corresponding author
- Monti, J. M.
- ORCID
- Monti, J. M.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 1989-10
- Volume
- 155
- Issue
- S6
- Pages
- 61-65
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2418274017
- Cited by
- 41
- References
- 0
- Citations by year
- 2019: 2 · 2017: 1 · 2016: 2 · 2015: 1 · 2012: 1
- FWCI
- 0.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The British Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
- Keywords
- moclobemide, depression, sleep, REM sleep, NREM sleep, sleep continuity, polysomnography, drug withdrawal, antidepressant effects
- MeSH terms
- Adult, Benzamides, Bipolar Disorder, Depressive Disorder, Electroencephalography, Evoked Potentials, Female, Humans, Male, Middle Aged, Monoamine Oxidase Inhibitors, Reaction Time, Sleep Stages, Sleep, REM, Moclobemide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
